Market Place
Sourcing Support
Aerovate Therapeutics to Explore Strategic Alternatives
08 Jul 2024 //
GLOBENEWSWIRE
Aerovate`s stock plummets after sole product fails in PAH trial
18 Jun 2024 //
FIERCE PHARMA
Aerovate Presents IMPAHCT Phase 2b Baseline Data At ATS 2024
21 May 2024 //
GLOBENEWSWIRE
Aerovate Therapeutics Q1 2024 Financials, Business Highlights
13 May 2024 //
GLOBENEWSWIRE
Aerovate to Present the Phase 2b Portion of the IMPAHCT Trial at the Conference
27 Mar 2024 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces Full-Year 2023 Financial Results
25 Mar 2024 //
GLOBENEWSWIRE
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
06 Mar 2024 //
GLOBENEWSWIRE
Aerovate Announces Completion of Enrollment in Phase 2b Trial Evaluating AV-101
20 Nov 2023 //
GLOBENEWSWIRE
Aerovate Announces Third Quarter Financial Results and Business Highlights
13 Nov 2023 //
GLOBENEWSWIRE
Aerovate Announces Second Quarter Financial Results and Business Highlights
14 Aug 2023 //
GLOBENEWSWIRE
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
11 Jul 2023 //
GLOBENEWSWIRE
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Aerovate Presents Nonclinical Pharmacokinetic Data in Support of AV-101
22 May 2023 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces First Quarter FYR and Business Highlights
15 May 2023 //
GLOBENEWSWIRE
Aerovate Announces Full-Year 2022 Financial Results and Business Highlights
29 Mar 2023 //
GLOBENEWSWIRE
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
02 Mar 2023 //
GLOBENEWSWIRE
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
23 Jan 2023 //
GLOBENEWSWIRE
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101
17 Nov 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Aerovate Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design
18 Oct 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics Presents Phase 1 Data for AV-101 in PAH
16 May 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces Full-Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference
02 Mar 2022 //
GLOBENEWSWIRE
Aerovate Initiates IMPAHCT Phase 2b/3 Trial of AV-101 In PAH
15 Dec 2021 //
PRESS RELEASE
Aerovate Therapeutics shares drop 26% in Russell 2000 Index debut
20 Sep 2021 //
SEEKINGALPHA
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
17 Sep 2021 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Aerovate Therapeutics Announces Closing of Initial Public Offering
02 Jul 2021 //
GLOBENEWSWIRE
A dry-powder lung disease drug and next-gen antibiotics
30 Jun 2021 //
ENDPTS
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
29 Jun 2021 //
GLOBENEWSWIRE
Brazil OK`s clinical tests for homegrown COVID vaccine Butanvac
10 Jun 2021 //
REUTERS
